Exchanges
BSE, NSE
Issue
Book building

Tamilnad Mercantile Bank IPO

₹509.65

−0.07% on listing

Listing-day close · NSE · 15 Sep 2022 · issue price ₹510

Tamilnad Mercantile Bank’s ₹808 crore IPO was priced at ₹510 a share. It listed on the NSE on 15 Sep 2022 and closed its first day at ₹509.65, down 0.07% on the issue price.

Timeline

  1. Opens
  2. Closes
  3. Allotment
  4. Refunds
  5. Shares in demat
  6. Listing

Issue details

Issue size
₹808 Cr
Fresh issue
₹808 Cr
Offer for sale
—
Lot size
28 shares
Minimum investment
₹14,280
Face value
₹10
Registrar
MUFG Intime India

Subscription

Tamilnad Mercantile Bank IPO subscription by investor category
CategoryShares offeredTimes subscribed
Total—1.98×

Overall, from the basis of allotment.

Financials and valuation

Market cap (post-issue)
₹8,313 Cr
ROE
16.58%
PAT margin
17.65%

From the offer documents.

Listing

Listing date
15 Sep 2022
Issue price
₹510
Open
₹495.00
High
₹515.00
Low
₹481.00
Close
₹509.65

Listing day on the NSE. The close was −0.07% on the issue price.

TMB share price today

FAQs

When did the Tamilnad Mercantile Bank IPO open and close?

It opened on 5 Sep 2022 and closed on 7 Sep 2022.

What was the Tamilnad Mercantile Bank IPO price?

The price band was ₹500–525 a share. The final issue price was ₹510.

What is the lot size and minimum investment?

One lot is 28 shares, ₹14,280 at ₹510 a share. Retail investors apply in whole lots.

How much did Tamilnad Mercantile Bank raise?

₹808 crore: ₹808 crore of new shares.

How many times was the Tamilnad Mercantile Bank IPO subscribed?

1.98 times overall.

How did Tamilnad Mercantile Bank list?

It listed on the NSE on 15 Sep 2022 at ₹495.00 and closed the day at ₹509.65, down 0.07% on the ₹510 issue price.

Who is the registrar of the Tamilnad Mercantile Bank IPO?

MUFG Intime India handles the allotment, refunds and credit of shares.

For information only. Not investment advice or a research report.

Full disclaimer

See how an IPO fits your plan

Armor checks every holding against your goals, risk and timeline.

Get the app